Sniff nasal inspiratory pressure as a prognostic factor of tracheostomy or death in amyotrophic lateral sclerosis

Journal of Neurology

Volumn 262, Issue 3, 2015, Pages 593-603

  Capozzo, Rosa ^a   Quaranta, Vitaliano N ^a   Pellegrini, Fabio ^b,c   Fontana, Andrea ^b   Copetti, Massimiliano ^b   Carratù, Pierluigi ^a   Panza, Francesco ^a   Cassano, Anna ^a   Falcone, Vito A ^a   Tortelli, Rosanna ^a   Cortese, Rosa ^a   Simone, Isabella L ^a   Resta, Onofrio ^a   Logroscino, Giancarlo ^a  

^a UNIVERSITY OF BARI   (Italy)

^b CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^c Consorzio Mario Negri Sud ^*  (Italy)

Author keywords

ALS; FVC; Prognosis; Respiratory function; SNIP

Indexed keywords

ADULT; AGED; AIRWAY PRESSURE; AMYOTROPHIC LATERAL SCLEROSIS; AMYOTROPHIC LATERAL SCLEROSIS FUNCTIONAL RATING SCALE; ARTICLE; ASSESSMENT OF HUMANS; COHORT ANALYSIS; DEATH; DISEASE DURATION; FEMALE; FOLLOW UP; HUMAN; INTUBATION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; RESPIRATORY FAILURE; RETROSPECTIVE STUDY; SNIFF NASAL INSPIRATORY PRESSURE; SURVIVAL; TERTIARY CARE CENTER; TRACHEOSTOMY; TRACHEOTOMY; AREA UNDER THE CURVE; BREATHING; MIDDLE AGED; MORTALITY; NONPARAMETRIC TEST; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; SURVIVAL ANALYSIS; VERY ELDERLY; VITAL CAPACITY;

ADULT; AGED; AGED, 80 AND OVER; AMYOTROPHIC LATERAL SCLEROSIS; AREA UNDER CURVE; FEMALE; HUMANS; MALE; MIDDLE AGED; RESPIRATION; RESPIRATORY INSUFFICIENCY; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; TRACHEOSTOMY; VITAL CAPACITY;

EID: 84925515352     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-014-7613-3     Document Type: Article

References (36)

1. Traynor BJ, Zhang H, Shefner JM, Schoenfeld D, Cudkowicz ME, NEALS Consortium (2004) Functional outcome measures as clinical trial endpoints in ALS. Neurology 63:1933–1935
2. Hardiman O, Kollewe K, Leigh PN, Pradat PF, Silani V, Tomik B, EALSC Working Group (2007) Good practice in the management of amyotrophic lateral sclerosis: clinical guidelines. An evidence-based review with good practice points. EALSC Working Group. Amyotroph Lateral Scler 8:195–213
3. Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O, Burrell JR, Zoing MC (2011) Amyotrophic lateral sclerosis. Lancet 377:942–955
4. Chiò A, Logroscino G, Hardiman O, Swingler R, Mitchell D, Beghi E, Traynor BG, Eurals Consortium (2009) Prognostic factors in ALS: a critical review. Amyotroph Lateral Scler 10:310–323
5. Schiffman PL, Belsh JM (1993) Pulmonary function at diagnosis of amyotrophic lateral sclerosis. Chest 103:508–513
6. Fallat RJ, Jewitt B, Bass M, Kamm B, Norris FH Jr (1979) Spirometry in amyotrophic lateral sclerosis. Arch Neurol 36:74–78
7. Gordon PH, Moore DH, Miller RG, Florence JM, Verheijde JL, Doorish C, Hilton JF, Spitalny GM, MacArthur RB, Mitsumoto H, Neville HE, Boylan K, Mozaffar T, Belsh JM, Ravits J, Bedlack RS, Graves MC, McCluskey LF, Barohn RJ, Tandan R, Western ALS Study Group (2007) Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol 6:1045–1053
8. UKMND-LiCALS Study Group, Morrison KE, Dhariwal S, Hornabrook R, Savage L, Burn DJ, Khoo TK, Kelly J, Murphy CL, Al-Chalabi A, Dougherty A, Leigh PN, Wijesekera L, Thornhill M, Ellis CM, O’Hanlon K, Panicker J, Pate L, Ray P, Wyatt L, Young CA, Copeland L, Ealing J, Hamdalla H, Leroi I, Murphy C, O’Keeffe F, Oughton E, Partington L, Paterson P, Rog D, Sathish A, Sexton D, Smith J, Vanek H, Dodds S, Williams TL, Steen IN, Clarke J, Eziefula C, Howard R, Orrell R, Sidle K, Sylvester R, Barrett W, Merritt C, Talbot K, Turner MR, Whatley C, Williams C, Williams J, Cosby C, Hanemann CO, Iman I, Philips C, Timings L, Crawford SE, Hewamadduma C, Hibberd R, Hollinger H, McDermott C, Mils G, Rafiq M, Shaw PJ, Taylor A, Waines E, Walsh T, Addison-Jones R, Birt J, Hare M, Majid T (2013) Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 12:339–345
9. Fitting JW, Paillex R, Hirt L, Aebischer P, Schluep M (1999) Sniff nasal pressure: a sensitive respiratory test to assess progression of amyotrophic lateral sclerosis. Ann Neurol 46:887–893
10. Black LF, Hyatt RE (1971) Maximal static respiratory pressures in generalized neuromuscular disease. Am Rev Respir Dis 103:641–650
11. Polkey MI, Green M, Moxham J (1995) Measurement of respiratory muscle strength. Thorax 50:1131–1135
12. Miller JM, Moxham J, Green M (1985) The maximal sniff in the assessment of diaphragm function in man. Clin Sci (Lond) 69:91–96
13. Lyall RA, Donaldson N, Polkey MI, Leigh PN, Moxham J (2001) Respiratory muscle strength and ventilatory failure in amyotrophic lateral sclerosis. Brain 124:2000–2013
14. Stefanutti D, Benoist MR, Scheinmann P, Chaussain M, Fitting JW (2000) Usefulness of sniff nasal pressure in patients with neuromuscular or skeletal disorders. Am J Respir Crit Care Med 162:1507–1511
15. Schmidt EP, Drachman DB, Wiener CM, Clawson L, Kimball R, Lechtzin N (2006) Pulmonary predictors of survival in amyotrophic lateral sclerosis: use in clinical trial design. Muscle Nerve 33:127–132
16. Morgan RK, McNally S, Alexander M, Conroy R, Hardiman O, Costello RW (2005) Use of Sniff nasal-inspiratory force to predict survival in amyotrophic lateral sclerosis. Am J Respir Crit Care Med 171:269–274
17. Von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, STROBE Initiative (2007) Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ 335:806–808
18. Brooks BR (1994) El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial “Clinical limits of amyotrophic lateral sclerosis” workshop contributors. J Neurol Sci 124(Suppl):96–107
19. Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, Nakanishi A (1999) The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci 169:13–21
20. Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383
21. Miller MR, Hankinson J, Brusasco V, Crapo RO, Burgos F, Casaburi R, Coates A, van der Grinten CP, Gustafsson P, Hankinson J, Jensen R, Johnson DC, MacIntyre N, McKay R, Miller MR, Navajas D, Pedersen OF, Wanger J, ATS, ERS Task Force (2005) Standardisation of spirometry. Eur Respir J 26:319–338
22. American Thoracic Society/European Respiratory Society (2002) ATS/ERS Statement on respiratory muscle testing. Am J Respir Crit Care Med 166:518–624
23. Pencina MJ, D’Agostino RB, Steyerberg EW (2011) Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 30:11–21
24. del Aguila MA, Longstreth WT Jr, McGuire V, Koepsell TD, van Belle G (2003) Prognosis in amyotrophic lateral sclerosis. A population-based study. Neurology 60:813–819
25. Wolf J, Safer A, Wöhrle JC, Palm F, Nix WA, Maschke M, Grau AJ (2014) Factors predicting one-year mortality in amyotrophic lateral sclerosis patients—data from a population-based registry. BMC Neurol 14:197
26. Polkey MI, Lyall RA, Green M, Nigel Leigh P, Moxham J (1998) Expiratory muscle function in amyotrophic lateral sclerosis. Am J Respir Crit Care Med 158:734–741
27. Kleopa KA, Sherman M, Neal B, Romano GJ, Heiman-Patterson T (1999) Bipap improves survival and rate of pulmonary function decline in patients with ALS. J Neurol Sci 164:82–88
28. Fregonezi G, Araújo PR, Macêdo TL, Dourado Junior ME, Resqueti VR, Andrade Ade F (2013) Monitoring respiratory muscle strength assists in early diagnosis of respiratory dysfunction as opposed to the isolated use of pulmonary function evaluation in amyotrophic lateral sclerosis. Arq Neuropsiquiatr 71:146–152
29. Baumann F, Henderson RD, Morrison SC, Brown M, Hutchinson N, Douglas JA, Robinson PJ, McCombe PA (2010) Use of respiratory function tests to predict survival in amyotrophic lateral sclerosis. Amyotroph Lateral Scler 11:194–202
30. Ward NS, Hill NS (2001) Pulmonary function testing in neuromuscular disease. Clin Chest Med 22:769–781
31. Vincken W, Elleker G, Cosio MG (1986) Detection of upper airway muscle involvement in neuromuscular disorders using the flow-volume loop. Chest 90:52–57
32. Carratù P, Cassano A, Gadaleta F et al (2011) Association between low sniff nasal-inspiratory pressure (SNIP) and sleep disordered breathing in amyotrophic lateral sclerosis: preliminary results. Amyotroph Lateral Scler 12:458–463
33. Uldry C, Fitting JW (1995) Maximal values of sniff nasal inspiratory pressure in healthy subjects. Thorax 50:371–375
34. Logroscino G, Traynor BJ, Hardiman O, Chio’ A, Couratier P, Mitchell JD, Swingler RJ, Beghi E, EURALS, (2008) Descriptive epidemiology of amyotrophic lateral sclerosis: new evidence and unsolved issues. J Neurol Neurosurg Psychiatry 79:6–11
35. Paesmans M, Sculier JP, Libert P, Bureau G, Dabouis G, Thiriaux J, Michel J, Van Cutsem O, Sergysels R, Mommen P (1995) Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party. J Clin Oncol 13:1221–1230
36. EFNS Task Force on Diagnosis and Management of Amyotrophic Lateral Sclerosis, Andersen PM, Abrahams S, Borasio GD, de Carvalho M, Chio A, Van Damme P, Hardiman O, Kollewe K, Morrison KE, Petri S, Pradat PF, Silani V, Tomik B, Wasner M, Weber M (2012) EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)—revised report of an EFNS task force. Eur J Neurol 19:360–375